3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 1/2
2
Phase 1
2
Phase NA
1
Phase EARLY_PHASE1
1
Phase 3
1
Phase 2/3
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Head & Neck
1
Breast
1
Conditions
Endometrial Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Breast Neoplasms
1
Breast Diseases
1
Interventions
pembrolizumab
35
Carboplatin
24
Specimen Handling
20
Cyclophosphamide
19
Magnetic Resonance Spectroscopy
18
fludarabine
15
Dexamethasone
15
Nivolumab
14
Gemcitabine
14
Bevacizumab
14
Biopsy
12
atezolizumab
11
Temozolomide
11
Paclitaxel
10
Docetaxel
10
Cisplatin
10
venetoclax
9
Rituximab
9
Pemetrexed
9
Ipilimumab
9
Prednisone
8
Lenalidomide
8
Fluorouracil
8
blinatumomab
7
Vincristine
7
Radiotherapy
7
Oxaliplatin
7
Capecitabine
7
olaparib
6
lenvatinib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Metformin
×
30 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT02755844
2026-05-27
ENDOLA
Hospices Civils de Lyon
Phase 1/2
Completed
35 enrolled